Acadian Asset Management’s Voyager Therapeutics VYGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.5M | Buy |
428,670
+179,799
| +72% | +$682K | ﹤0.01% | 1149 |
|
|
2026
Q1 | $957K | Buy |
248,871
+148,388
| +148% | +$584K | ﹤0.01% | 1175 |
|
|
2025
Q4 | $394K | Sell |
100,483
-50,395
| -33% | -$223K | ﹤0.01% | 1375 |
|
|
2025
Q3 | $702K | Sell |
150,878
-5,837
| -4% | -$21.1K | ﹤0.01% | 1136 |
|
|
2025
Q2 | $486K | Sell |
156,715
-73,993
| -32% | -$239K | ﹤0.01% | 1145 |
|
|
2025
Q1 | $778K | Buy |
230,708
+206,758
| +863% | +$966K | ﹤0.01% | 987 |
|
|
2024
Q4 | $135K | Sell |
23,950
-16,318
| -41% | -$105K | ﹤0.01% | 1318 |
|
|
2024
Q3 | $235K | Sell |
40,268
-66,557
| -62% | -$484K | ﹤0.01% | 1307 |
|
|
2024
Q2 | $843K | Sell |
106,825
-353,025
| -77% | -$2.96M | ﹤0.01% | 1051 |
|
|
2024
Q1 | $4.28M | Buy |
459,850
+42,029
| +10% | +$355K | 0.01% | 508 |
|
|
2023
Q4 | $3.52M | Sell |
417,821
-212,342
| -34% | -$1.54M | 0.01% | 539 |
|
|
2023
Q3 | $4.88M | Sell |
630,163
-89,496
| -12% | -$817K | 0.02% | 445 |
|
|
2023
Q2 | $8.24M | Sell |
719,659
-22,696
| -3% | -$235K | 0.03% | 336 |
|
|
2023
Q1 | $5.72M | Buy |
742,355
+73,617
| +11% | +$585K | 0.03% | 425 |
|
|
2022
Q4 | $4.08M | Buy |
668,738
+109,189
| +20% | +$620K | 0.02% | 501 |
|
|
2022
Q3 | $3.31M | Buy |
559,549
+180,147
| +47% | +$1.15M | 0.02% | 509 |
|
|
2022
Q2 | $2.24M | Buy |
379,402
+131,432
| +53% | +$888K | 0.01% | 601 |
|
|
2022
Q1 | $1.89M | Sell |
247,970
-300,100
| -55% | -$1.34M | 0.01% | 682 |
|
|
2021
Q4 | $1.48M | Sell |
548,070
-223,905
| -29% | -$764K | 0.01% | 742 |
|
|
2021
Q3 | $2.03M | Buy |
771,975
+105,121
| +16% | +$341K | 0.01% | 673 |
|
|
2021
Q2 | $2.75M | Buy |
666,854
+173,617
| +35% | +$787K | 0.01% | 623 |
|
|
2021
Q1 | $2.32M | Buy |
493,237
+389,434
| +375% | +$2.66M | 0.01% | 699 |
|
|
2020
Q4 | $741K | Buy |
103,803
+81,522
| +366% | +$784K | ﹤0.01% | 1085 |
|
|
2020
Q3 | $238K | Sell |
22,281
-155,581
| -87% | -$1.83M | ﹤0.01% | 1388 |
|
|
2020
Q2 | $2.24M | Sell |
177,862
-52,706
| -23% | -$613K | 0.01% | 706 |
|
|
2020
Q1 | $2.11M | Buy |
230,568
+41,923
| +22% | +$481K | 0.01% | 587 |
|
|
2019
Q4 | $2.63M | Buy |
188,645
+138,271
| +274% | +$2.01M | 0.01% | 600 |
|
|
2019
Q3 | $867K | Sell |
50,374
-20,231
| -29% | -$425K | ﹤0.01% | 933 |
|
|
2019
Q2 | $1.92M | Buy |
70,605
+24,105
| +52% | +$552K | 0.01% | 631 |
|
|
2019
Q1 | $890K | Buy |
46,500
+469
| +1% | +$6.11K | ﹤0.01% | 926 |
|
|
2018
Q4 | $433K | Buy |
+46,031
| New | +$591K | ﹤0.01% | 940 |
|
|
2018
Q3 | – | Sell |
-32,747
| Closed | -$640K | – | 1809 |
|
|
2018
Q2 | $640K | Buy |
32,747
+29,536
| +920% | +$584K | ﹤0.01% | 834 |
|
|
2018
Q1 | $60K | Buy |
+3,211
| New | +$69.4K | ﹤0.01% | 1330 |
|
|
2016
Q4 | – | Sell |
-30
| Closed | – | – | 1781 |
|
|
2016
Q3 | $0 | Sell |
30
-1,735
| -98% | -$23.5K | ﹤0.01% | 1562 |
|
|
2016
Q2 | $20K | Buy |
1,765
+556
| +46% | +$6.8K | ﹤0.01% | 1134 |
|
|
2016
Q1 | $11K | Buy |
+1,209
| New | +$13.7K | ﹤0.01% | 1183 |
|
Other funds holding VYGR
AC
VCM
VPM
EAM
Acadian Asset Management's VYGR Position: Q2 2026 in Review
Acadian Asset Management increased its Voyager Therapeutics (VYGR) stake by 72% in Q2 2026, buying an estimated $682K and bringing the position to 428,670 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1149.
Acadian Asset Management first reported a position in VYGR in Q1 2016 and has held it in 36 quarters since. The position peaked at $8.24M in Q2 2023. 112 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.
- Acadian Asset Management held 428,670 shares of Voyager Therapeutics worth $1.5M as of Q2 2026.
- Acadian Asset Management bought 179,799 Voyager Therapeutics shares in Q2 2026, an estimated $682K.
- Voyager Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1149 holding.
- Acadian Asset Management first reported a position in Voyager Therapeutics in Q1 2016 and has held it in 36 quarters since.
- Acadian Asset Management's Voyager Therapeutics position peaked at $8.24M in Q2 2023.
- 112 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.
Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.